[Biosimilars in oncology].
Sérgio Barroso(Hospital do Espírito Santo), Adriana Teixeira, J. S. De Oliveira Coutinho, José Dinis(Instituto Português de Oncologia Francisco Gentil), Helena Gervásio(Instituto Português de Oncologia de Coimbra Francisco Gentil), Margarida Damasceno, A Parreira(IPO Porto), Anabela Sá, Fernando Leal da Costa(University of Alabama at Birmingham), Helena Rodrigues, Fernando Prı́ncipe, Ana Marques Pereira, João F. Lacerda(University of Lisbon)
PubMed
November 16, 2009
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation
|New England Journal of Medicine|2014|301
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266